Edaravone diminishes free radicals from circulating neutrophils in patients with ischemic brain attack.
OBJECTIVE
Treatment with a free radical scavenger could be a new option for ischemic brain attack, however, little is known about the alteration of oxidative stress markers induced by edaravone, a novel free radical scavenger, in human ischemic brain attack.


METHODS
We investigated the effects of edaravone on the oxidative stress markers in patients with ischemic brain attack. Twenty-one patients with ischemic brain attack and 19 controls were enrolled in this study. Blood samples were obtained just before and soon after the first administration of edaravone (30 mg) or ozagrel (40 mg). Intracellular reactive oxygen species of neutrophils were measured using 6-carboxy-2', 7'-dichlorodihydrofluorescin diacetate and a fluorescence-activated cell sorter. Superoxide from neutrophils, induced by phorbol myristate acetate (PMA), was determined by luminol-amplified chemiluminescence assay.


RESULTS
Treatment with 30 mg of edaravone significantly decreased the intracellular reactive oxygen species (ROS) of neutrophils (Wilcoxon test, p=0.0001) and PMA-induced superoxide produced by neutrophils (Wilcoxon test, p=0.001). Ozagrel did not alter the intracellular ROS or superoxide production of neutrophils.


CONCLUSIONS
Reduction of intracellular ROS and suppression of superoxide production in neutrophils provide a potential explanation for the clinical efficacy of edaravone in patients with ischemic brain attack.
The First Department of Medicine, Asahikawa Medical College, Asahikawa
Hitoshi
H
Aizawa
Yoshihiro
Y
Makita
Kazuhiro
K
Sumitomo
Yoko
Y
Aburakawa
Takayuki
T
Katayama
Setsu
S
Nakatani-Enomoto
Yasuhiro
Y
Suzuki
Kazuhiko
K
Fujiwara
Hiroyuki
H
Enomoto
Kenji
K
Kuroda
Takashi
T
Kimura
Osamu
O
Yahara
Satoshi
S
Koyama
Junichi
J
Maruyama
Masao
M
Nakamura
Naoyuki
N
Hasebe
Kenjiro
K
Kikuchi
D000368:Aged; D000369:Aged, 80 and over; D000983:Antipyrine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002545:Brain Ischemia / Q000097:blood* / Q000188:drug therapy*; D000077553:Edaravone; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D005609:Free Radicals / Q000378:metabolism*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism*; D018384:Oxidative Stress / Q000187:drug effects*
D016166:Free Radical Scavengers; D005609:Free Radicals; D000077553:Edaravone; D000983:Antipyrine